Advertisement

JSA Advises Multiples Private Equity Fund's Investment In BDR Pharmaceuticals

BDR Pharma is recognised as a leading CDMO player in Indian pharmaceutical industry and is valued at INR 7500 crores.

Multiples Private Equity Fund’s investment in BDR Pharmaceuticals International Private Limited

JSA advised and represented Multiples Private Equity Fund (“Multiples”) in an investment of INR 685 crores by a consortium of investors led by Multiples for a 9.3% stake in BDR Pharmaceuticals International Private Limited (“BDR Pharma”). This is the first investment into the company.

BDR Pharma is recognised as a leading CDMO player in Indian pharmaceutical industry and is valued at INR 7500 crores. The company focuses on therapeutic segments such as oncology and critical care with a growing presence in dermatology and gynaecology. BDR Pharma shot to fame during Covid-19 for developing copies of antivirals such as remdesivir, favipiravir, molnupiravir and lyophilized amphotericin b injection.

JSA team comprised

    Anand Lakra
    Lead Partner

  Niharika Mepani
 Principal Associate

      Ami Shah
      Associate

      Jinay Shah
        Associate

  Sonakshi Verma
       Associate

 

JSA Employment team

  

  Maneesh Upadhyay
          Partner  

  Ashrafi Ginwalla
  Senior Associate

 

 

 

 

JSA competition team


   Vaibhav Choukse
 Partner & Head of Practice                    (Competition Law)

         Ela Bali
  Principal Associate 

     Nripi Jolly
   Senior Associate




Tags assigned to this article:

Around The World

Advertisement